Resmed INC Form 4 insider transactions

Michael J. Rider, Global General Counsel of ResMed Inc., reports a disposition of shares for tax withholding and stock purchase plan activity.

Director Carol Burt reported a gift of ResMed shares to The Nature Conservancy on May 24, 2024.

ResMed director Jan De Witte amended a previous SEC filing to indicate a stock sale was executed under a pre-arranged Rule 10b5-1 trading plan.

Director Peter C. Farrell gifted 68,200 shares of ResMed common stock to a charitable remainder trust, resulting in a decrease in his directly held shares.

Director Jan De Witte sold 360 shares of ResMed Inc. on May 15, 2024, at a price of $218.29 per share.

ResMed's Chief Financial Officer, Brett Sandercock, exercised stock options and sold shares of ResMed common stock on May 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Director Carol Burt reported a gift of ResMed shares to a charitable organization on April 29, 2024.

Director Karen Drexler sold 425 shares of ResMed Inc. common stock at a price of $214.92 on April 29, 2024.

Michael J. Rider, Global General Counsel of ResMed Inc., reports the sale of 81 shares of common stock at $180 per share.

Michael J. Rider, Global General Counsel of ResMed Inc., reports selling 200 shares of ResMed Common Stock on March 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.